Solesence SLSN
- Market cap
- $56.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $55.4M
- −14% on a year ago
- Net margin
- −3.8%
- Free cash flow yield
- −1.5%
Solesence trades at 1.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $55.4M over the last twelve months, down 14% on a year earlier with a −4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8M−18% | $8M−3% | $9.9M+4% | $13M+10% | $16.9M+112% | $12.6M+57% | $14.6M+48% | $20.4M+56% | $14.6M−14% | $12.5M−1% | $13M−11% | $15.3M−25% | |
| Cost of revenue | $6.4M−11% | $7.5M+3% | $6.3M−14% | $9.3M+14% | $10.8M+68% | $9.8M+30% | $11.2M+79% | $13.9M+50% | $11.2M+4% | $9M−8% | $9.8M−13% | $10.6M−24% |
| Gross profit | $1.5M−39% | $471K−51% | $3.6M+67% | $3.7M+2% | $6.1M+299% | $2.8M+487% | $3.4M−6% | $6.4M+72% | $3.4M−45% | $3.4M+24% | $3.1M−7% | $4.7M−26% |
| R&D | $1.1M+25% | $785K+8% | $910K−9% | $864K−13% | $970K−8% | $1.1M+39% | $1M+12% | $955K+11% | $1.1M+12% | $1M−5% | $1M+2% | $947K−1% |
| SG&A | $1.7M−26% | $1.6M−24% | $1.6M−28% | $1.8M−13% | $1.9M+14% | $1.9M+20% | $2.1M+35% | $3M+65% | $3.1M+59% | $2.2M+17% | $2.8M+33% | $3.7M+22% |
| −$1.2M+93% | −$1.9M+2% | $1.1M | $1M+81% | $3.2M | −$223K−88% | $256K−77% | $2.5M+137% | −$781K | $186K | −$700K | $121K−95% | |
| Interest expense | $214K+85% | $225K+50% | $218K+41% | $191K−22% | $153K−29% | $108K−52% | $176K−19% | $87K−55% | $339K+122% | $328K+204% | $263K+49% | $279K+221% |
| Pre-tax income | −$1.4M+92% | −$2.1M+6% | $893K | $856K+157% | $3M | −$331K−84% | $80K−91% | $3.6M+323% | −$1.1M | −$154K−54% | −$962K | −$158K |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $390K | $0 | −$317K | n/a | n/a | |
| Net income | −$1.4M+92% | −$2.1M+7% | $893K | $856K+157% | $3M | −$558K−74% | $80K−91% | $3.2M+278% | −$1.1M | $163K | −$962K | −$158K |
| −$0.03+50% | −$0.04+0% | $0.02 | $0.01+0% | $0.04 | −$0.01−75% | $0.00 | $0.04+300% | −$0.02 | $0.00 | −$0.01 | $0.00 | |
| 49.6M+1% | 49.6M+1% | 58M+17% | 58.7M+17% | 71.9M+45% | 70M+41% | 72.6M+25% | 72.6M+24% | 70.5M−2% | 72.1M+3% | 70.6M−3% | 70.6M−3% |
EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY10 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Consumer Defensive nearest Solesence's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SLSNSolesence | $56.5M | n/m | 81.0× | 1.0× | −14% | −3.8% | |
| DITAmcon Distributing | $59.9M | 32.4× | 14.2× | 0.0× | +7% | 0.1% | |
| AXILAxil Brands | $37.7M | 16.2× | 34.4× | 1.3× | +10% | 9.3% | |
| RAVERave Restaurant | $31.3M | 10.5× | 13.8× | 2.4× | +7% | 22.3% | |
| JVACoffee | $25.6M | 5.4× | 23.0× | 0.3× | +8% | 4.9% | |
| LGCYLegacy Education | $131.3M | 15.3× | 18.1× | 1.6× | +25% | 11.4% | |
| LWAYLifeway Foods | $339.3M | 32.1× | 31.2× | 1.4× | +26% | 4.5% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| ARKOARKO | $427.4M | 54.4× | 23.9× | 0.1× | −2% | 0.2% | |
| WEYSWeyco | $484.2M | 14.0× | 12.2× | 1.7× | −0% | 12.4% | |
| Peer median | $59.9M | 15.3× | 18.1× | 1.3× | +7% | 8.6% |
More on Solesence
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
Valuation data, not investment advice. Prices as of .